Skip to main content
300 Collins St Melbourne
hello@pivot.net
Login
Signup
Main navigation
About
Team
Contact
Research & Development
Innovation Engine
Therapeutic Focus
Development Strategy
Publications/Presentations
Pipeline
RMC-4630 (SHP2)
RMC-5552 (mTORC1/4EBP1)
SOS1
RAS(ON) Inhibitors
Investors
Careers
Publications/Presentations
Header
Publication / Presentation
October 24, 2020
Intermittent dosing of RMC-4630, a potent, selective inhibitor of SHP2, combined with the MEK inhibitor cobimetinib, in a phase 1b/2 clinical trial for advanced solid tumors with activating mutations of RAS signaling
Read more
Publication / Presentation
September 29, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity
Read more
Publication / Presentation
September 16, 2020
Approaches to Inhibiting RAS Driven Tumors Beyond KRAS-G12C
Read more
Publication / Presentation
June 22, 2020
SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
Read more
Publication / Presentation
June 22, 2020
Dual inhibition of SHP2 and CDK4/6 leads to immunological memory and immune-mediated anti-tumor activity in a mouse syngeneic model of breast cancer
Read more
